∙ Patients may be included in the study if they meet ALL of the following criteria:

• 1\. Patients must have a Stage II primary invasive cutaneous melanoma (pT2b-pT4b, AJCC 8th edition) with Breslow thickness \>1.0mm to 2.0mm; \>2.0mm to 4.0mm or \>4.0mm with ulceration, or \>2.0mm to 4.0mm; or \>4.0mm without ulceration (Table 1) as determined by diagnostic biopsy (narrow excision, incision, shave or punch biopsy) and subsequent histopathological analysis.

• Must have a primary melanoma that is cutaneous (including head, neck, trunk, extremity, scalp, palm or sole).

• An uninterrupted 2cm margin must be technically feasible around biopsy scar or primary melanoma.

• 4\. Surgical intervention (which refers to the staging -SLNB and WLE as these are both to be done on the same day) must be completed within 120 days of the original diagnosis. Surgical intervention must also be performed within 28 days of randomisation.

• Patients must be 18 years or older at time of consent.

• Patient must be able to give informed consent and comply with the treatment protocol and follow up plan.

• Life expectancy of at least 5 years from the time of diagnosis, not considering the melanoma in question, as determined by the PI.

• Patients must have an ECOG performance score between 0 and 1 at screening.

• A survivor of prior cancer is eligible provided that ALL of the following criteria are met and documented:

‣ The patient has undergone potentially curative therapy for all prior malignancies,

⁃ There has been no evidence of recurrence of any prior malignancies for at least FIVE years (with the exception of successfully treated uterine/cervical or non-melanoma skin cancers (SCCs/BCCs) with no evidence of recurrence), and

⁃ The patient is deemed by their treating physician to be at low risk of recurrence from previous malignancies.